Simplicity Wealth LLC Makes New $162,000 Investment in Ventyx Biosciences, Inc. (NASDAQ:VTYX)

Simplicity Wealth LLC acquired a new position in Ventyx Biosciences, Inc. (NASDAQ:VTYX) in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 29,405 shares of the company’s stock, valued at approximately $162,000.

Other large investors have also modified their holdings of the company. Tower Research Capital LLC TRC raised its position in shares of Ventyx Biosciences by 1,424.6% during the 4th quarter. Tower Research Capital LLC TRC now owns 19,927 shares of the company’s stock worth $49,000 after purchasing an additional 18,620 shares during the last quarter. Federated Hermes Inc. acquired a new position in shares of Ventyx Biosciences during the 4th quarter worth about $50,000. Norden Group LLC acquired a new position in shares of Ventyx Biosciences during the 1st quarter worth about $59,000. Aigen Investment Management LP acquired a new position in shares of Ventyx Biosciences during the 4th quarter worth about $65,000. Finally, Jump Financial LLC acquired a new position in shares of Ventyx Biosciences during the 4th quarter worth about $72,000. Institutional investors and hedge funds own 97.88% of the company’s stock.

Ventyx Biosciences Stock Down 1.8 %

Shares of Ventyx Biosciences stock traded down $0.08 during mid-day trading on Friday, hitting $4.37. The stock had a trading volume of 341,647 shares, compared to its average volume of 913,055. The firm has a 50-day moving average of $4.98 and a two-hundred day moving average of $3.93. Ventyx Biosciences, Inc. has a 12-month low of $1.87 and a 12-month high of $40.58. The firm has a market cap of $308.09 million, a P/E ratio of -1.35 and a beta of 0.48.

Ventyx Biosciences (NASDAQ:VTYX) last posted its quarterly earnings results on Thursday, May 9th. The company reported ($0.62) earnings per share for the quarter, beating the consensus estimate of ($0.67) by $0.05. During the same quarter in the previous year, the firm posted ($0.68) earnings per share. Sell-side analysts expect that Ventyx Biosciences, Inc. will post -2.31 earnings per share for the current year.

Analyst Ratings Changes

Several research analysts recently weighed in on the stock. Oppenheimer upgraded shares of Ventyx Biosciences from a “market perform” rating to an “outperform” rating and set a $12.00 price target for the company in a research report on Tuesday, March 12th. Canaccord Genuity Group dropped their price objective on shares of Ventyx Biosciences from $16.00 to $15.00 and set a “buy” rating for the company in a research note on Wednesday, March 13th. Wells Fargo & Company raised shares of Ventyx Biosciences from an “equal weight” rating to an “overweight” rating and upped their price objective for the company from $7.00 to $16.00 in a research note on Tuesday, March 12th. Finally, Lifesci Capital raised shares of Ventyx Biosciences from a “market perform” rating to an “outperform” rating in a research note on Wednesday, February 28th. Four equities research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $21.75.

Ventyx Biosciences Company Profile

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease.